Effect of paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and Ledipasvir/Sofosbuvir regimens on survival compared with untreated hepatitis C virus-infected persons: Results from ERCHIVES

Clinical Infectious Diseases

Volumn 65, Issue 6, 2017, Pages 1006-1011

  Butt, Adeel Ajwad ^a,b   Yan, Peng ^a   Simon, Tracey G ^c   Abou Samra, Abdul Badi ^b,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HAMAD MEDICAL CORPORATION   (Qatar)

Author keywords

ERCHIVES; HCV; PrOD; Sofosbuvir ledipasvir; Survival

Indexed keywords

ALCOHOL; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; LEDIPASVIR PLUS SOFOSBUVIR; VIRUS RNA; ABT-267; ABT-333; ABT-450; ANILIDE; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; CARBAMIC ACID DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR; MACROCYCLIC COMPOUND; RITONAVIR; SOFOSBUVIR; SULFONAMIDE; URACIL;

ADULT; AGED; ALCOHOL ABUSE; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BLACK PERSON; CAUCASIAN; CHRONIC KIDNEY FAILURE; CLINICAL OUTCOME; COHORT ANALYSIS; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DRUG ABUSE; DRUG DEPENDENCE; FEMALE; FOLLOW UP; HEPATITIS C; HISPANIC; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBESITY; PRIORITY JOURNAL; PROPENSITY SCORE; SURVIVAL; SUSTAINED VIROLOGIC RESPONSE; ANALOGS AND DERIVATIVES; CHRONIC HEPATITIS C; KAPLAN MEIER METHOD; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE;

AGED; ANILIDES; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CARBAMATES; DRUG THERAPY, COMBINATION; FEMALE; FLUORENES; HEPATITIS C, CHRONIC; HUMANS; KAPLAN-MEIER ESTIMATE; MACROCYCLIC COMPOUNDS; MALE; MIDDLE AGED; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RITONAVIR; SOFOSBUVIR; SULFONAMIDES; SURVIVAL RATE; SUSTAINED VIROLOGIC RESPONSE; URACIL;

EID: 85031941008     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix364     Document Type: Article

References (21)

1. Majumdar A, Kitson MT, Roberts SK. Systematic review: Current concepts and challenges for the direct-Acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther 2016; 43:1276-92.
2. US Food and Drug Administration. Hepatitis B and C treatments. Available at: http://www.fda.gov/forpatients/illness/hepatitisbc/ucm408658.htm. Accessed 2 January 2017.
3. Butt AA, Wang X, Moore CG. Effect of hepatitis C virus and its treatment on survival. Hepatology 2009; 50:387-92.
4. Simmons B, Saleem J, Heath K, Cooke GS, Hill A. Long-Term treatment outcomes of patients infected with hepatitis C virus: A systematic review and meta-Analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis 2015; 61:730-40.
5. Rutter K, Stattermayer AF, Beinhardt S, et al. Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C. Aliment Pharmacol Ther 2015; 41:521-31.
6. Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-Acting antivirals. J Hepatol 2016; 65:727-33.
7. Reig M, Marino Z, Perello C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016; 65:719-26.
8. Butt AA, Yan P, Shaikh OS, Chung RT, Sherman KE; ERCHIVES study. Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: Results from ERCHIVES. Liver Int 2016; 36:651-8.
9. Rogal SS, Yan P, Rimland D, et al; Electronically Retrieved Cohort of HCV Infected Veterans Study Group. Incidence and progression of chronic kidney disease after hepatitis C seroconversion: Results from ERCHIVES. Dig Dis Sci 2016; 61:930-6.
10. Erqou S, Mohanty A, Murtaza Kasi P, Butt AA. Predictors of mortality among United States veterans with human immunodeficiency virus and hepatitis C virus coinfection. ISRN Gastroenterol 2014; 2014:764540.
11. Butt AA, Wang X, Moore CG. Effect of hepatitis C virus and its treatment on survival. Hepatology 2009; 50:387-92.
12. Kaplan DE, Dai F, Aytaman A, et al. Development and performance of an algorithm to estimate the Child-Turcotte-Pugh score from a national electronic healthcare database. Clin Gastroenterol Hepatol 2015; 13:2333-41.e1-6.
13. Butt AA, Fultz SL, Kwoh CK, Kelley D, Skanderson M, Justice AC. Risk of diabetes in HIV infected veterans pre-And post-HAART and the role of HCV coinfection. Hepatology 2004; 40:115-9.
14. Butt AA, McGinnis K, Rodriguez-Barradas MC, et al; Veterans Aging Cohort Study. HIV infection and the risk of diabetes mellitus. AIDS 2009; 23:1227-34.
15. Butt AA, Wang X, Fried LF. HCV infection and the incidence of CKD. Am J Kidney Dis 2011; 57:396-402.
16. Butt AA, Khan UA, McGinnis KA, Skanderson M, Kent Kwoh C. Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. J Viral Hepat 2007; 14:890-6.
17. Peterson ED, Shaw LK, DeLong ER, Pryor DB, Califf RM, Mark DB. Racial variation in the use of coronary-revascularization procedures-Are the differences real? Do they matter? N Engl J Med 1997; 336:480-6.
18. Bach PB, Cramer LD, Warren JL, Begg CB. Racial differences in the treatment of early-stage lung cancer. N Engl J Med 1999; 341:1198-205.
19. Butt AA, Tsevat J, Leonard AC, et al. Effect of race and HIV co-infection upon treatment prescription for hepatitis C virus. Int J Infect Dis 2009; 13:449-55.
20. Emmanuel B, Shardell MD, Tracy L, Kottilil S, El-Kamary SS. Racial disparity in all-cause mortality among hepatitis C virus-infected individuals in a general US population, NHANES III. J Viral Hepat 2016. doi:10.1111/jvh.12656.
21. Butt AA, Khan UA, Skanderson M. Comorbidities and their impact on mortality in HCV and HCV-HIV-coinfected persons on dialysis. J Clin Gastroenterol 2008; 42:1054-59.